HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?

ABSTRACT:

Background

Despite the extensive use of bevacizumab in a range of oncology indications, the US FDA revoked its approval for breast cancers, and multiple negative trials in several solid malignancies have been reported, so the need for predictive biomarkers has increased. The development of predictive biomarkers for anti-angiogenic bevacizumab therapy has long been pursued but without success.

Introduction

Heat shock protein (HSP)-27 expression has recently been identified as a predictive biomarker for bevacizumab in treating metastatic melanoma. This study aimed to evaluate the cost effectiveness of HSP27 biomarker testing before administration of bevacizumab.

Methods

A partitioned survival analysis model with three mutually exclusive health states (progression-free s

SUBMITTER: Seo MK 

PROVIDER: S-EPMC7426343 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature